Client NewsRoquefort Therapeutics plc: Appointment of Strategic & Scientific Advisor
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that Professor Trevor M. Jones CBE FMedSci, has been appointed as advisor to the Board with immediate effect.
Prof. Jones has had a distinguished career in the pharmaceutical and biotech industry spanning over 45 years, having previously been main Board Director for Research & Development at The Wellcome Foundation (Wellcome plc), where he was responsible for the development of a number of significant products across several therapeutic areas attracting reimbursement, as well as OTC formulations. Prof. Jones also served as a Non-Executive Director of Allergan Inc from 2004 to 2015 during which time the company made a number of key acquisitions.
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.